

COVAX Global Supply Forecast

September 8, 2021

CEPI




COVAX Facility Supply Forecast

Ranged forecasts under low, most likely, and high scenarios

PRELIMINARY AND SUBJECT TO ASSUMPTIONS

COVAX Forecasted Supply, Cumulative, M doses, 2021 and 2022¹

— Low scenario⁴ — Most likely scenario⁴ — High scenario⁴



THREE BIGGEST DRIVERS OF UNCERTAINTY FOR COVAX SUPPLY

- **Timing and extent to which export controls in India are eased.** Easing of restrictions in Q4 could enable the release of hundreds of millions of doses to COVAX across both SII-AstraZeneca and SII-Novavax (latter pending regulatory approval)
- **Manufacturers prioritizing supply from global manufacturing networks to COVAX,** allowing COVAX to access doses that it has already secured and paid for under its existing APAs.
- **Timely regulatory approval** of candidates that COVAX has signed deals with including those being developed by Novavax, SII-Novavax, and Clover.

¹ Timing of available supply is based on anticipated date of release by manufacturer, at which point doses become available for delivery. Timing of delivery to countries will be lagged due to need for local regulatory approvals, supply agreements, country readiness, export licenses, logistics, etc. Volumes for expected single-dose regimen candidates doubled to ensure comparability across vaccines. Volumes include dose donations that are committed to being delivered through COVAX. Volumes have been rounded to nearest 5M.

² Final SFP volumes may be lower than forecasted based on opt-out and dose-sharing behavior. Volumes only account for current SFP demand based on Commitment Agreements.

³ Coverage refers to proportion of total population in AMC91 Participants that could be fully vaccinated with available volumes, assuming India receives 20% of AMC-funded volumes.

⁴ Scenarios are based on best available information from manufacturers and analysis from Gavi and UNICEF on the impact and likelihood of potential mitigation efforts.


Key changes since last supply forecast update (July 2021)

- Since the last COVAX supply forecast, published in July 2021, the evolving supply landscape has led to a reduction of ~25% in anticipated volumes available for supply in 2021.
- The specific factors driving these changes are:
 - (+) **Sinopharm**: Volumes brought forward from 2022 into 2021 following successful discussions with manufacturer.
 - (+) **Dose donations**: Additional doses committed from donors covering the AstraZeneca, J&J and Moderna vaccines.
 - (-) **J&J**: Production issues at J&J's Emergent facility (which is assigned to supply COVAX) have led to delays. While production has now restarted, the manufacturing ramp-up combined with the backlog of orders for other bilateral customers has led to delayed timelines and lower volumes that will be made available to COVAX in 2021.
 - (-) **SII-AstraZeneca and SII-Novavax**: Continued export restrictions from India are leading to further supply delays, with the current most likely scenario assuming no SII supply to COVAX in 2021. COVAX remains in close dialogue with the Government of India.
 - (-) **AstraZeneca**: Technical issues at manufacturing sites assigned to supply COVAX have led to supply delays.
 - (-) **Novavax**: Delays to original regulatory strategy have resulted in delays in expected supply to COVAX (as WHO Emergency Use Listing (EUL) or Stringent Regulatory Authority (SRA) approval required for supply to COVAX participants).
 - (-) **Clover**: Supply timelines take into account potential risks related to regulatory timelines (as WHO EUL or SRA approval required for supply to COVAX participants).
- The graph on the next slide breaks down the impact of these changes in terms of volumes.

Drivers of variance between COVAX supply forecasts

July vs. September forecasts

M doses, total anticipated supply available by manufacturer in 2021¹



The evolving supply landscape has led to a reduction of ~25% in anticipated volumes available for supply in 2021 through COVAX.

¹ Forecasts are based on best available information from manufacturers and analysis from Gavi and UNICEF. Timing of available supply is based on anticipated date of release by manufacturer, at which point doses become available for delivery. Timing of delivery to countries will be lagged due to need for local regulatory approvals, supply agreements, country readiness, export licenses, logistics, etc. Volumes have been rounded to nearest 5M.

² Actual volume is 90M doses, with volumes for expected single-dose regimen candidates doubled to ensure comparability across vaccines.

³ Additional dose donations confirmed since July include vaccines from the following manufacturers: AstraZeneca, J&J, and Moderna.

⁴ Based on current "most likely" scenario.